vs
COMPASS MINERALS INTERNATIONAL INC（CMP）与Guardant Health, Inc.（GH）财务数据对比。点击上方公司名可切换其他公司
COMPASS MINERALS INTERNATIONAL INC的季度营收约是Guardant Health, Inc.的1.4倍（$396.1M vs $281.3M），COMPASS MINERALS INTERNATIONAL INC净利率更高（4.7% vs -45.7%，领先50.4%），Guardant Health, Inc.同比增速更快（39.4% vs 28.9%），Guardant Health, Inc.自由现金流更多（$-54.2M vs $-59.8M），过去两年Guardant Health, Inc.的营收复合增速更高（29.2% vs 4.3%）
指南针矿产国际是一家美国上市矿产企业，总部位于堪萨斯州欧弗兰帕克，是盐、氯化镁和硫酸钾等产品的领先生产商。公司面向北美和英国客户供应经处理与未经处理的散装道路除冰盐，同时向全球种植者提供植物营养产品，此外也生产民用除冰、水质调节产品及相关商用产品。
Guardant Health, Inc.是总部位于美国加利福尼亚州帕洛阿尔托的生物技术企业，由Helmy Eltoukhy与AmirAli Talasaz联合创立，目前二人共同出任公司首席执行官，统筹公司战略规划与日常运营管理工作。
CMP vs GH — 直观对比
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $396.1M | $281.3M |
| 净利润 | $18.6M | $-128.5M |
| 毛利率 | 16.0% | 64.6% |
| 营业利润率 | 9.2% | -43.0% |
| 净利率 | 4.7% | -45.7% |
| 营收同比 | 28.9% | 39.4% |
| 净利润同比 | 178.8% | -15.8% |
| 每股收益（稀释后） | $0.43 | $-1.01 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $396.1M | $281.3M | ||
| Q3 25 | $227.5M | $265.2M | ||
| Q2 25 | $214.6M | $232.1M | ||
| Q1 25 | $494.6M | $203.5M | ||
| Q4 24 | $307.2M | $201.8M | ||
| Q3 24 | $208.8M | $191.5M | ||
| Q2 24 | $202.9M | $177.2M | ||
| Q1 24 | $364.0M | $168.5M |
| Q4 25 | $18.6M | $-128.5M | ||
| Q3 25 | $-7.2M | $-92.7M | ||
| Q2 25 | $-17.0M | $-99.9M | ||
| Q1 25 | $-32.0M | $-95.2M | ||
| Q4 24 | $-23.6M | $-111.0M | ||
| Q3 24 | $-48.3M | $-107.8M | ||
| Q2 24 | $-43.6M | $-102.6M | ||
| Q1 24 | $-38.9M | $-115.0M |
| Q4 25 | 16.0% | 64.6% | ||
| Q3 25 | 16.9% | 64.7% | ||
| Q2 25 | 19.2% | 65.0% | ||
| Q1 25 | 15.5% | 63.3% | ||
| Q4 24 | 11.2% | 61.6% | ||
| Q3 24 | 9.3% | 61.1% | ||
| Q2 24 | 16.1% | 59.1% | ||
| Q1 24 | 19.7% | 61.2% |
| Q4 25 | 9.2% | -43.0% | ||
| Q3 25 | 5.3% | -37.3% | ||
| Q2 25 | 7.4% | -45.9% | ||
| Q1 25 | -0.6% | -54.6% | ||
| Q4 24 | 0.2% | -62.4% | ||
| Q3 24 | -14.3% | -61.3% | ||
| Q2 24 | 2.9% | -56.8% | ||
| Q1 24 | -10.8% | -59.2% |
| Q4 25 | 4.7% | -45.7% | ||
| Q3 25 | -3.2% | -35.0% | ||
| Q2 25 | -7.9% | -43.0% | ||
| Q1 25 | -6.5% | -46.8% | ||
| Q4 24 | -7.7% | -55.0% | ||
| Q3 24 | -23.1% | -56.3% | ||
| Q2 24 | -21.5% | -57.9% | ||
| Q1 24 | -10.7% | -68.2% |
| Q4 25 | $0.43 | $-1.01 | ||
| Q3 25 | — | $-0.74 | ||
| Q2 25 | $-0.41 | $-0.80 | ||
| Q1 25 | $-0.77 | $-0.77 | ||
| Q4 24 | $-0.57 | $-0.90 | ||
| Q3 24 | $-1.17 | $-0.88 | ||
| Q2 24 | $-1.05 | $-0.84 | ||
| Q1 24 | $-0.94 | $-0.94 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $46.7M | $378.2M |
| 总债务越低越好 | $890.0M | $1.5B |
| 股东权益账面价值 | $260.5M | $-99.3M |
| 总资产 | $1.5B | $2.0B |
| 负债/权益比越低杠杆越低 | 3.42× | — |
8季度趋势，按日历期对齐
| Q4 25 | $46.7M | $378.2M | ||
| Q3 25 | $59.7M | $580.0M | ||
| Q2 25 | $79.4M | $629.1M | ||
| Q1 25 | $49.5M | $698.6M | ||
| Q4 24 | $45.8M | $525.5M | ||
| Q3 24 | $20.2M | $585.0M | ||
| Q2 24 | $12.8M | $933.7M | ||
| Q1 24 | $38.3M | $1.0B |
| Q4 25 | $890.0M | $1.5B | ||
| Q3 25 | $839.8M | $1.1B | ||
| Q2 25 | $833.4M | $1.1B | ||
| Q1 25 | $807.6M | $1.1B | ||
| Q4 24 | $974.4M | $1.1B | ||
| Q3 24 | $921.2M | — | ||
| Q2 24 | $875.1M | — | ||
| Q1 24 | $877.2M | — |
| Q4 25 | $260.5M | $-99.3M | ||
| Q3 25 | $234.1M | $-354.5M | ||
| Q2 25 | $249.8M | $-305.5M | ||
| Q1 25 | $236.5M | $-250.8M | ||
| Q4 24 | $263.0M | $-139.6M | ||
| Q3 24 | $316.6M | $-60.1M | ||
| Q2 24 | $352.1M | $-1.6M | ||
| Q1 24 | $400.4M | $68.3M |
| Q4 25 | $1.5B | $2.0B | ||
| Q3 25 | $1.5B | $1.3B | ||
| Q2 25 | $1.5B | $1.3B | ||
| Q1 25 | $1.5B | $1.3B | ||
| Q4 24 | $1.7B | $1.5B | ||
| Q3 24 | $1.6B | $1.5B | ||
| Q2 24 | $1.6B | $1.6B | ||
| Q1 24 | $1.7B | $1.7B |
| Q4 25 | 3.42× | — | ||
| Q3 25 | 3.59× | — | ||
| Q2 25 | 3.34× | — | ||
| Q1 25 | 3.41× | — | ||
| Q4 24 | 3.70× | — | ||
| Q3 24 | 2.91× | — | ||
| Q2 24 | 2.49× | — | ||
| Q1 24 | 2.19× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-37.0M | $-26.4M |
| 自由现金流经营现金流 - 资本支出 | $-59.8M | $-54.2M |
| 自由现金流率自由现金流/营收 | -15.1% | -19.3% |
| 资本支出强度资本支出/营收 | 5.8% | 9.9% |
| 现金转化率经营现金流/净利润 | -1.99× | — |
| 过去12个月自由现金流最近4个季度 | $94.1M | $-233.1M |
8季度趋势，按日历期对齐
| Q4 25 | $-37.0M | $-26.4M | ||
| Q3 25 | $-6.9M | $-35.4M | ||
| Q2 25 | $21.8M | $-60.3M | ||
| Q1 25 | $186.9M | $-62.7M | ||
| Q4 24 | $-4.1M | $-64.5M | ||
| Q3 24 | $-12.7M | $-51.1M | ||
| Q2 24 | $-6.8M | $-94.0M | ||
| Q1 24 | $86.2M | $-30.3M |
| Q4 25 | $-59.8M | $-54.2M | ||
| Q3 25 | $-22.8M | $-45.8M | ||
| Q2 25 | $3.8M | $-65.9M | ||
| Q1 25 | $172.9M | $-67.1M | ||
| Q4 24 | $-25.9M | $-83.4M | ||
| Q3 24 | $-33.6M | $-55.3M | ||
| Q2 24 | $-21.5M | $-99.1M | ||
| Q1 24 | $56.2M | $-37.2M |
| Q4 25 | -15.1% | -19.3% | ||
| Q3 25 | -10.0% | -17.3% | ||
| Q2 25 | 1.8% | -28.4% | ||
| Q1 25 | 35.0% | -33.0% | ||
| Q4 24 | -8.4% | -41.3% | ||
| Q3 24 | -16.1% | -28.9% | ||
| Q2 24 | -10.6% | -55.9% | ||
| Q1 24 | 15.4% | -22.1% |
| Q4 25 | 5.8% | 9.9% | ||
| Q3 25 | 7.0% | 3.9% | ||
| Q2 25 | 8.4% | 2.4% | ||
| Q1 25 | 2.8% | 2.2% | ||
| Q4 24 | 7.1% | 9.4% | ||
| Q3 24 | 10.0% | 2.2% | ||
| Q2 24 | 7.2% | 2.9% | ||
| Q1 24 | 8.2% | 4.1% |
| Q4 25 | -1.99× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CMP
| Highway Deicing Salt | $210.8M | 53% |
| Consumer Industrial Salt | $120.7M | 30% |
| Plant Nutrition | $60.8M | 15% |
| Transferred Over Time | $2.8M | 1% |
| Other | $1.0M | 0% |
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
